Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
18 studies found for:    sangamo
Show Display Options
Rank Status Study
1 Not yet recruiting Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
Condition: Mucopolysaccharidosis II
Intervention: Biological: SB-913
2 Not yet recruiting Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
Condition: MPS I
Intervention: Genetic: SB-318
3 Recruiting Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
Condition: Hemophilia B
Intervention: Biological: SB-FIX
4 Not yet recruiting Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Genetic: SB-525
5 Completed Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Conditions: HIV Infection;   HIV Infections
Intervention: Genetic: SB-728-T
6 Completed Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: SB-509
7 Completed Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy
Interventions: Drug: SB-509;   Other: Saline
8 Active, not recruiting Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Genetic: SB-728mR-T;   Drug: Cyclophosphamide
9 Active, not recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
10 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
11 Completed Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy
Interventions: Drug: SB-509;   Drug: Placebo
12 Active, not recruiting Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
Condition: Idiopathic Parkinson's Disease
Interventions: Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin;   Procedure: Sham Surgery
13 Active, not recruiting Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF;   Procedure: Placebo Surgery
14 Completed Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy
Interventions: Biological: SB-509;   Other: Placebo
15 Completed Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy
Interventions: Drug: SB-509;   Other: Normal Saline
16 Completed Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy
Condition: Diabetic Neuropathy
Intervention: Genetic: hVEGF-A
17 Recruiting Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
Condition: HIV
Intervention: Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning
18 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption

Study has passed its completion date and status has not been verified in more than two years.